WallStreetZenWallStreetZen

NASDAQ: SNOA
Sonoma Pharmaceuticals Inc Stock

$0.17+0.00 (+0%)
Updated Mar 28, 2024
SNOA Price
$0.17
Fair Value Price
N/A
Market Cap
$2.59M
52 Week Low
$0.12
52 Week High
$1.52
P/E
-0.18x
P/B
0.39x
P/S
0.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.31M
Earnings
-$5.08M
Gross Margin
36.7%
Operating Margin
-41.62%
Profit Margin
-41.2%
Debt to Equity
1.18
Operating Cash Flow
-$5M
Beta
0.52
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SNOA Overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SNOA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SNOA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SNOA is good value based on its book value relative to its share price (0.39x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.19x)
P/B vs Industry Valuation
SNOA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SNOA due diligence checks available for Premium users.

Be the first to know about important SNOA news, forecast changes, insider trades & much more!

SNOA News

Valuation

SNOA fair value

Fair Value of SNOA stock based on Discounted Cash Flow (DCF)
Price
$0.17
Fair Value
$1.29
Undervalued by
86.84%
SNOA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SNOA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.18x
Industry
54.21x
Market
44.51x

SNOA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.39x
Industry
2.19x
SNOA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SNOA's financial health

Profit margin

Revenue
$3.1M
Net Income
-$866.0k
Profit Margin
-27.6%
SNOA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SNOA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$14.6M
Liabilities
$7.9M
Debt to equity
1.18
SNOA's short-term assets ($12.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNOA's short-term assets ($12.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNOA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SNOA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.1M
Investing
-$1.0k
Financing
$1.3M
SNOA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SNOA vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
SNOA$2.59M+0.61%-0.18x0.39x
LSDI$2.46M+4.66%-0.20x30.27x
CPHI$2.45M-12.71%-0.22x0.40x
YCBD$2.83M-7.92%-0.07x0.40x
PRFX$3.15M+2.25%-0.25x0.43x

Sonoma Pharmaceuticals Stock FAQ

What is Sonoma Pharmaceuticals's quote symbol?

(NASDAQ: SNOA) Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol SNOA. Sonoma Pharmaceuticals stock quotes can also be displayed as NASDAQ: SNOA.

If you're new to stock investing, here's how to buy Sonoma Pharmaceuticals stock.

What is the 52 week high and low for Sonoma Pharmaceuticals (NASDAQ: SNOA)?

(NASDAQ: SNOA) Sonoma Pharmaceuticals's 52-week high was $1.52, and its 52-week low was $0.12. It is currently -89.08% from its 52-week high and 43.1% from its 52-week low.

How much is Sonoma Pharmaceuticals stock worth today?

(NASDAQ: SNOA) Sonoma Pharmaceuticals currently has 15,607,433 outstanding shares. With Sonoma Pharmaceuticals stock trading at $0.17 per share, the total value of Sonoma Pharmaceuticals stock (market capitalization) is $2.59M.

Sonoma Pharmaceuticals stock was originally listed at a price of $2,457.00 in Jan 25, 2007. If you had invested in Sonoma Pharmaceuticals stock at $2,457.00, your return over the last 17 years would have been -99.99%, for an annualized return of -43.16% (not including any dividends or dividend reinvestments).

How much is Sonoma Pharmaceuticals's stock price per share?

(NASDAQ: SNOA) Sonoma Pharmaceuticals stock price per share is $0.17 today (as of Mar 28, 2024).

What is Sonoma Pharmaceuticals's Market Cap?

(NASDAQ: SNOA) Sonoma Pharmaceuticals's market cap is $2.59M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sonoma Pharmaceuticals's market cap is calculated by multiplying SNOA's current stock price of $0.17 by SNOA's total outstanding shares of 15,607,433.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.